【請先報名，線上課程】Evening Talk with Experts – Breakthroughs of BRAF V600E-Mutant mCRC on ASCO 2025

【請先報名，線上課程】Evening Talk with Experts – Breakthroughs of BRAF V600E-Mutant mCRC on ASCO 2025
日期：114年6月18日 晚上7:00-8:30
主講人：Dr. Takayuki Yoshino、梁逸歆醫師
主辦單位：中華民國癌症醫學會
協辦單位：皮耶法鉑公司

報名網址：https://pse.is/7gkgbu
報名時請詳填資訊。

本會醫師 5分

BRAF V600E-mutant metastatic colorectal cancer (mCRC) is a particularly aggressive subtype of CRC with poor prognosis. Recently, there are some emerging regimens improving the treatment outcome of BRAF V600E-mutant mCRC patients. The BEACON study is a phase III clinical trial that evaluated the efficacy and safety of combining Encorafenib and Cetuximab in patients with BRAF V600E-mutant mCRC who had received one or two prior lines of therapy. This study demonstrated significant improvement in OS, PFS, and ORR, compared to standard chemotherapy. Due to the result of BEACON study, FDA and EMA approve Encorafenib in combination with Cetuximab in the treatment of BRAF-mutant mCRC patients. So far, Encorafenib is the only BRAF inhibitor approved in CRC. On step further, the BREAKWATER study investigates the efficacy and safety of Encorafenib in combination with Cetuximab and Chemotherapy as a first-line treatment of BRAF-mutant mCRC patients . On ASCO 2025, preliminary outcome of this study showed Encorafenib + Cetuximab + Chemotherapy significantly improved ORR, PFS, and OS than traditional Chemotherapy +/- Bevacizumab, which could become future SoC and largely improved the outcome of this subtype.